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Abstract
Lesch-Nyhan disease (LND) is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine
phosphoribosyltransferase (HPRT). In contrast, HPRT-deficiency in the mouse does not result in the profound phenotypes
such as self-injurious behavior observed in humans, and the genetic basis for this phenotypic disparity between HPRT-
deficient humans and mice is unknown. To test the hypothesis that HPRT deficiency is modified by the presence/absence of
phosphoribosyltransferase domain containing 1 (PRTFDC1), a paralog of HPRT that is a functional gene in humans but an
inactivated pseudogene in mice, we created transgenic mice that express human PRTFDC1 in wild-type and HPRT-deficient
backgrounds. Male mice expressing PRTFDC1 on either genetic background were viable and fertile. However, the presence
of PRTFDC1 in the HPRT-deficient, but not wild-type mice, increased aggression as well as sensitivity to a specific
amphetamine-induced stereotypy, both of which are reminiscent of the increased aggressive and self-injurious behavior
exhibited by patients with LND. These results demonstrate that PRTFDC1 is a genetic modifier of HPRT-deficiency in the
mouse and could therefore have important implications for unraveling the molecular etiology of LND.
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Introduction
The first mouse genetic model of a human disease developed by
germline transmission of a selected mutation in embryonic stem
cells was Lesch-Nyhan disease (LND, MIM: 300322) [1,2,3]. LND
is an X-linked metabolic disease is caused by mutations in a purine
salvage enzyme, hypoxanthine phosphoribosyltransferase (HPRT,
EC 2.4.2.8), and results in profound developmental, neurological
and behavioral phenotypes, including aggressive and self-injurious
behavior [4]. While HPRT-deficiency in the mouse does result in
reduced basal ganglia dopamine (DA) [5,6], which is thought to be
important for the neurobehavioral phenotypes observed in LND
[7], except for an increased sensitivity to amphetamine, no other
behavioral phenotypes have been associated with the loss of
HPRT activity in the mouse [6,8]. The phenotypic disparity
between humans and mice deficient for HPRT led to the
hypothesis that purine metabolism differed in some way between
these two species, and that uncovering of the basis for such a
difference would likely provide important insights into LND [6,9].
However, attempts to improve the mouse model of LND by
generating double mutants of HPRT and other purine metabolic
enzymes have failed to identify genetic factors that contribute to
the interspecies phenotypic disparity in HPRT-deficiency [4,10].
Genetic alteration of the mouse genome to account for
differences in gene content between humans and mice can be
critical for creating more accurate models of human disease, e.g.
[11,12,13]. Previously, we reconstructed the evolutionary history
of the HPRT gene family in vertebrates and inferred that a paralog
of HPRT, called phosphoribosyltransferase domain containing 1
(PRTFDC1), arose via a duplication of HPRT prior to the radiation
of vertebrates [14]. Despite its antiquity and presence in the
genome of humans and all other sampled vertebrates, we
discovered that PRTFDC1 had been inactivated in the mouse
lineage [14]. Two previous observations lead us to hypothesize
that the presence of PRTFDC1 in humans and the absence of a
functional copy of this gene in mice could contribute to the
phenotypic disparity of HPRT-deficiency between those species.
First, since there is unvalidated evidence that the HPRT and
PRTFDC1 proteins may physically interact with one another [15],
the regulation, or activity of PRTFDC1 might be altered when
HPRT is absent or mutated. Second, though it is not known if
PRTFDC1 has biologically relevant phosphoribosyltransferase
activity [16], because the activity of other phosphoribosyltrans-
ferases with known enzymatic activity has been reported to be
increase in the absence of HPRT due to elevated levels of a
common substrate, 5-phosphoribosyl-1-pyrophosphate (PRPP) ,
reviewed in [4], the activity of PRTFDC1 has the potential to be
similarly affected. We therefore proposed that when HPRT is
absent or mutated, the altered activity and/or protein-protein
interactions of PRTFDC1 enhance the phenotypic severity of
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22381HPRT-deficiency. Thus, the lack of a functional PRTFDC1 gene
in the mouse effectively suppresses the HPRT-deficient pheno-
types in that species. Here we report the results of our experiments
designed to empirically test for a genetic interaction between
HPRT and PRTFDC1 in the mouse.
Materials and Methods
Generation and breeding of the transgenic mice
All experimental protocols using mice were approved by the
Emory University IACUC and meet the guidelines of the
American Association for Accreditation of Laboratory Animal
Care. The IACUC approval number for this study is 192-2008.
Human bacterial artificial chromosome (BAC) clone RP11-129O7
was used to generate transgenic mice by pronuclear injection into
an FVB background. Four transgenic founders were identified by
PCR using primers specific for the human BAC (see Materials and
Methods S1). The transgenic lines were expanded and maintained
as heterozygotes while being backcrossed into C57BL/6 (Charles
River strain 027). Mice carrying a null allele of Hprt [2] that had
been bred into the C57BL/6 background were purchased from
The Jackson Laboratory (B6.129P2-Hprt1
b-m3/J, stock number
002171) and maintained as a closed breeding colony. After five
generations of backcrossing into the C57BL/6 background, males
hemizygous for Tg(RP11-129O7)9 and Tg(RP11-129O7)13 were
crossed to females (Hprt
2/2, Hprt
+/2 and Hprt
+/+) from the Hprt
colony to produce wild-type and HPRT-deficient males with or
without the transgene. Protocols used to genotype the transgenic
and HPRT-deficient mice are provided in the Materials and
Methods S1.
Behavioral assays
General. All mice were reared in a specific pathogen-free
facility with a 12 hr light/dark cycle (lights on - 7 am; lights off - 7
pm). Food and water were available ad libitum except during
behavioral testing. All experiments were carried out in a quiet,
isolated behavior room between 8:00 am and 5:00 pm. Mice were
moved to this room at least 24 hr before testing.
Locomotor activity. Locomotor activity was assessed using
an automated system (San Diego Instruments, La Jolla, CA, USA)
with photobeams that recorded ambulations (consecutive beam
breaks). For exploratory behavior, mice were placed individually
in the chambers and allowed to explore for 2 hr, and all
ambulations recorded. For circadian activity, mice were kept in
the chambers following their novel activity test for an additional
24 hr. Total ambulations were recorded.
Amphetamine-induced stereotypy. Amphetamine-induced
stereotypy was assessed as we have described previously [17]. Drug
naı ¨ve mice were placed individually in locomotor-monitoring
chambers for 2 hr and then injected with amphetamine (5 mg/kg,
i.p.). 30 min after injection, mice were videotaped for a 30-min
test. The test was scored for stereotypy by a trained and blinded
observer by breaking the 30 min into 10-sec bins, and recording
the predominant behavior the mouse was engaged in during each
bin.
Resident-Intruder aggression. Resident-intruder aggression
was assessed as we have described previously [18]. An intruder
male mouse was introduced into the cage of the resident mouse
for a 5-min videotaped session. Events were scored by a trained
observer blind to genotype and included whether the resident
mouse attacked the intruder mouse, latency to first attack, and
number of attacks. This test was then repeated twice, with two
days in between each test, for a total of three trials.
Statistical analysis
All data is presented as mean 6 SEM. Exploratory locomotor
behavior and nail-biting stereotypy were analyzed using a one-way
ANOVA. Circadian locomotor activity, aggression latency, and
aggression attack number were analyzed with a two-way repeated
measures ANOVA. Stereotypy behavior was analyzed with a one-
way ANOVA. Bonferroni post hoc tests were conducted following
ANOVA analysis. Percentage of attackers was assessed with a Chi
square contingency table, followed by Bonferroni post hoc tests,
adjusted for multiple comparisons. Statistical analysis was
conducted using Graphpad
TM Prism 4.0c for Macintosh or PC
(San Diego, CA).
Monoamine neurotransmitter assays
Mice were sacrificed by CO2, decapitated, the brains removed,
and the regions of interest dissected on ice. HPLC analysis with
electrochemical detection was performed as described previously
[19] with minor modifications.
Tissue collection and gene and protein expression assays
Tissues were dissected from p0, p28 and 7 week-old males,
immediately frozen on dry ice and stored at 280uC. Total RNA
was isolated from the tissues with either the RNeasy Lipid Tissue
Mini Kit (Qiagen) or Trizol (Invitrogen). The isolated mouse total
RNA, and total human RNA (Clontech and US Biologics)
was used as a template to generate cDNA (in duplicate) using
Superscript II Reverse Transcriptase (Invitrogen) primed with an
oligo(dT) primer according to manufacturer’s recommendations.
Quantitative RT-PCR reactions (n=4 replicates per cDNA
template) were performed using PlatinumH SYBRH Green qPCR
SuperMix-UDG (Invitrogen) and Roche LightCycler V3 using
commercially available primers for human PRTFDC1, and species-
specific primers for HPRT1, POLR2A, and ACTB (SuperArray
Bioscience Corp.). Western blots were performed using protein
extracts from mouse tissue probed with antibodies to PRTFDC1
(ProteinTech Group, Inc, 11986-1-AP) and a control protein,
ACTB (Santa Cruz Biotechnology, Inc, sc-20975).
Results
Mice expressing PRTFDC1 are viable and fertile
Four lines of transgenic mice (Tg(RP11-129O7)9, 13, 14 and 36)
were generated using a human BAC clone that contains the
PRTFDC1 locus (Fig. S1). RT-PCR confirmed that the human
PRTFDC1 gene was expressed in all the transgenic lines (Fig. S2).
In the wild-type genetic background males and females hemizy-
gous for the transgene from all the transgenic lines were viable,
fertile, and visibly indistinguishable from their littermates. Two of
the transgenic lines, Tg(RP11-129O7)9 and Tg(RP11-129O7)13,
were arbitrarily selected to create HPRT-deficient mice expressing
the transgene (hereafter designated as Hprt
2/0/Tg) and subjected
to more detailed molecular and phenotypic characterization. The
Hprt
2/0/Tg males were viable, fertile, and did not differ with
respect to their wild-type, HPRT-deficient (Hprt
2/0), or
PRTFDC1 trangenic (Tg) littermates in any gross phenotypes.
The presence of the transgene also had no effect in either the wild-
type or Hprt
2/0 background on exploratory or circadian locomotor
activity (Fig. S3A and B).
Increased aggression in HPRT-deficient mice expressing
PRTFDC1
LND patients tend to display an increased level of aggressive
behavior [20]. To determine if the expression of PRTFDC1
A Genetic Modifier of HPRT-Deficiency in the Mouse
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22381increased aggressive behavior in the HPRT-deficient mice, we
performed a resident-intruder test on wild-type, Hprt
2/0, Tg, and
Hprt
2/0/Tg males. The aggression of the Hprt
2/0/Tg males
increased in each successive trial, whereas a similar trend of
increasing aggression was not observed in the other genotypes
(Fig. 1A–C). As a consequence, in the third trial the Hprt
2/0/Tg
males had the highest percentage of individuals that attacked the
intruder (Fig. 1A), displayed significantly shorter latency to attack
(Fig. 1B), and significantly higher number of attacks (Fig. 1C) than
the other genotypes. A two-way repeated measures ANOVA of
latency to first attack revealed a significant interaction effect
between genotype and trial (F(6,106)=3.981, p=0.0012), as well as
main effects of both genotype (F(3,106)=4.533, p=0.0067) and
trial (F(2,106)=10.66, p,0.001). When number of attacks were
analyzed, there was a main effect of both genotype (F(3,106)
=2.942, p=0.0413) and trial (F(2,106)=4.459, p=0.0138), in
addition to a significant interaction between genotype and trial
(F(6,106)=2.375, p=0.0342). While the Hprt
2/0males did display
the highest average number of attacks in the second trial this result
wasprimarily dueto a single individualand notwas not significantly
different than the other genotypes.
Increased sensitivity to amphetamine-induced
stereotypy in HPRT-deficient mice expressing PRTFDC1
Due to the DA deficit in the basal ganglia, it was hypothesized
these Hprt
2/0 mice might be more sensitive to drugs that interact
with the DA systems and it was reported that mice deficient for
HPRT can be more sensitive to amphetamine-induced stereotypic
behavior [8]. To assess if the presence of the transgene affected
the behavioral response of Hprt
2/0 males to amphetamine, we
quantified and compared the behavior of wild-type, Hprt
2/0, Tg,
and Hprt
2/0/Tg males after the administration of amphetamine
(5 mg/kg, i.p.). Amphetamine induced two main types of
behaviors in all genotypes: locomotor behavior and excessive
sniffing stereotypy. These behaviors were seen at comparable
levels in all genotypes, though there is a trend towards decreased
locomotion in the Hprt
2/0males (Fig. 2A–B). However, the
Hprt
2/0/Tg mice did significantly differ from all other genotypes
with respect to a peculiar stereotypical behavior that was only
observed following the administration of amphetamine (Fig. 2C).
The majority (9/15) of Hprt
2/0/Tg displayed a distinctive
hunched posture, with their forepaws off the ground, and their
head angled downwards. The mice brought their forepaws toward
their mouths in a repetitive motion, while bobbing their heads
toward the paws, and appeared to be biting or chewing (Video S1).
This behavior is henceforth referred to as nail biting, although
subsequent examination of the paws and nails did not reveal any
physical damage. Shorter bouts of his behavior were observed in 6
out of the 11 Hprt
2/0 males, but never in the Tg (n=18) or wild-
type (n=12) animals. Other stereotypy behaviors including
freezing, head bobbing, and rearing were also seen, though to a
very minimal extent, in mice of all genotypes.
PRTFDC1 expression does not alter neurotransmitter
levels in the brain
A reduction in DA levels in the basal ganglia is thought to be
important for the neurobehavioral phenotypes observed in LND
[7]. HPRT-deficiency in the mouse also results in a reduction in
dopamine levels in the basal ganglia, albeit to a lesser degree than
is observed in LND patients [5]. To determine if the presence of
the transgene altered the level of DA (or other monoamine
neurotransmitters) in wild-type and Hprt
2/0 genetic backgrounds,
we compared the levels DA, norepinephrine (NE), epinephrine,
Figure 1. Resident-Intruder aggression. Mice (n=11–17 per
genotype) were tested for intruder aggression in three separate trials,
with two days between trials. (A) Percentage of residents that attacked
the intruder at each trial. * P,0.05 for overall differences between
genotypes within the same trial trial. { P,0.05 comparing Hprt
2/0/Tg to
wild-type (WT) and Tg within the same trial. (B) Mean latency to attack 6
SEM for each genotype during each trial; * P,0.05 comparing Hprt
2/0/Tg
to all other genotypes withinthe same trial. (C) Numberof attacks 6 SEM
foreach genotype during each trial;* P,0.05comparingHprt
2/0/Tgto all
other genotypes within the same trial.
doi:10.1371/journal.pone.0022381.g001
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nucleus accumbens (NAc), and olfactory bulb (OB) across
genotypes. Consistent with previous reports, DA levels were
significantly reduced in the Hprt
2/0 (n=7) compared to the wild-
type mice (n=9) in both sampled regions of the basal ganglia, the
CP and NAc (p,0.05, see Fig. 3 and Fig. S4A), but not the OB
(Fig. S4B). The presence of the transgene did not result in a
significant difference in the DA levels in either the wild-type or
Hprt
2/0 genetic backgrounds (Fig. 3 and Fig. S4), though there
was a trend toward lower DA levels in the CP of Hprt
2/0
/Tg compared to Hprt
2/0 males (Fig. 3). Thus, the behavioral
phenotypes we observed in the Hprt
2/0/Tg males were not
associated with a further reduction of DA in the basal ganglia. No
significant differences in the level of norepinephrine, epinephrine,
DOPAC, 5-HIAA and 5-HT were observed between genotypes in
any of the sampled brain regions.
PRTFDC1 is expressed in tissues affected in LND
The brain and testes are two tissues directly affected in male
LND patients [4] and database searches indicated that PRTFDC1
is expressed in those and other tissues in normal humans. To
empirically determine if PRTFDC1 is expressed in normal human
brain and testes, and if that were also the case in the transgenic
mice, we quantified the transcript level of PRTFDC1 and HPRT by
RT-PCR. PRTFDC1 and HPRT transcripts were detected in the
brain, testes and liver at all stages of development assayed in
humans (Fig. S5). Likewise, the PRTFDC1 transgene was expressed
in those three tissues at all time-points assayed in Tg and Hprt
2/0/
Figure 3. Dopamine levels in the caudoputamen. DA levels were
measured in wild-type (n=9), Hprt
2/0 (n=7), Tg (n=12) and Hprt
2/0/Tg
(n=14) males. Data shown is ng/mg of tissue 6 SEM. * P,0.05
comparing Hprt
2/0 and Hprt
2/0/Tg to wild-type. { P,0.05 comparing
Hprt
2/0/Tg to wild-type and Tg.
doi:10.1371/journal.pone.0022381.g003
Figure 2. Amphetamine-induced stereotypy. Mice (n=11–17 per
genotype) were scored for stereotypy behaviors following the
administration of 5 mg/kg amphetamine. Predominant behaviors were
locomotor behavior (A), sniffing stereotypy (B), and nail-biting-like
stereotypy (C). Shown is mean time of each behavior 6 SEM during the
30 min recorded test. * P,0.05 comparing Hprt
2/0/Tg to all other
genotypes. No differences were seen between genotypes for locomotor
behavior or sniffing stereotypy.
doi:10.1371/journal.pone.0022381.g002
A Genetic Modifier of HPRT-Deficiency in the Mouse
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22381Tg males (Fig. S6), and the PRTFDC1 protein was also detected in
Tg and Hprt
2/0/Tg males (Fig. 4).
Discussion
The molecular connection between deficiency of the purine
salvage enzyme HPRT and the developmental and neurobehav-
ioral phenotypes observed in LND patients is unknown [4]. Here
we have demonstrated that PRTFDC1, a gene that arose from an
ancient duplication event of HPRT, and is thus linked to purine
metabolism by its evolutionary history, is a genetic modifier of
HPRT-deficiency in the mouse. Specifically, we did not detect any
significant differences between PRTFDC1 transgenic and wild-
type mice. However, Hprt
2/0/Tg mice did differ from wild-type,
Tg, and Hprt
2/0 mice in two phenotypes of relevance to LND;
aggression and sensitivity to a specific amphetamine-induced
stereotypy. While the phenotypes of the Hprt
2/0/Tg mice do not
recapitulate the full spectrum of severe phenotypes observed in
LND patients, these results do support a genetic interaction in
mice between HPRT and PRTFDC1 in which the presence/
absence of PRTFDC1 acts as an enhancer/suppressor of HPRT-
deficiency. Nevertheless, it is also clear from our findings that the
presence of a functional copy of PRTFDC1 in humans is not solely
responsible for the phenotypic disparity between LND patients
and HPRT-deficient mice. Thus, other as of yet unidentified
factors must also contribute to the qualitative and quantitative
difference in phenotypes caused by the loss of HPRT in mouse and
man.
We propose the identification of a genetic interaction between
HPRT and PRTFDC1 in the mouse is significant for the following
reasons. First, while the brains of Hprt
2/0 mice are not normal, e.g.
[5,21], the increased aggression observed in Hprt
2/0/Tg mice is to
our knowledge the only spontaneous behavioral phenotype
observed in mice deficient for HPRT. Moreover, because
increased aggression is a hallmark feature of LND [20], the
Hprt
2/0/Tg mice are an improved model for studying that aspect
of the human disease. Second, the enhancement of an amphet-
amine-induced stereotypy in Hprt
2/0/Tg but not Tg males is
consistent with the genetic interaction between HPRT and
PRTFDC1 affecting striatal function. Depleted levels of DA in
the basal ganglia are found in LND patients, and there is strong
support for the reduction of DA at an early age being important
for the neurological and behavioral phenotypes associated with
LND [7]. The increased sensitivity of Hprt
2/0 mice to amphet-
amine but lack of spontaneous neurological and behavioral
phenotypes are thought to be a consequence of the milder
depletion of DA in the basal ganglia of HPRT-deficient mice
compared to LND patients [6,8]. Though the average DA level in
one region of the basal ganglia, the caudate putamen, was lower in
Hprt
2/0/Tg versus Hprt
2/0 mice, this difference was not
significant. Furthermore, none of the other assayed neurotrans-
mitter levels were altered by the presence of the transgene. Thus,
while we cannot pinpoint a specific molecular basis for the further
increase in sensitivity to amphetamine in Hprt
2/0/Tg mice, further
investigation of other aspects controlling dopamine neurotrans-
mission, such as dopamine release and receptor signaling
pathways, is warranted.
Finally, the enhancement of the nail-biting like stereotypy in the
in Hprt
2/0/Tg is tantalizingly reminiscent of the spontaneous self-
injurious behavior, specifically finger biting, observed in LND
patients [4] (Video S1). Amphetamine-induced stereotypy was
previously reported to be elevated in HPRT-deficient mice [8].
However, because of methodological differences in the quantifi-
cation and description of amphetamine-induced between the
studies, we can not directly compare the frequency of the specific
stereotypy we found to be elevated in Hprt
2/0 males expressing
PRTFDC1 to those found in [8]. It is important to emphasize that
the nail-biting like stereotypy reported here would not qualify as
the self-mutilation that has been observed in a rat model of that
aspect of LND that is based upon the drug-induced neonatal loss
of dopaminergic neurons [22]. Nonetheless, it is striking that the
presence of PRTFDC1 in Hprt
2/0 mice modified only this one
particular stereotypy, which we have rarely if ever observed in any
other wild-type or mutant strains, including those with amphet-
amine hypersensitivity (e.g. [17].
In conclusion, we have demonstrated a genetic interaction
between HPRT and PRTFDC1 in the mouse that is relevant to at
least a subset of the phenotypes observed in LND. Though
PRTFDC1 does contain a phosphoribosyltransferase domain, it
has yet to be determined if this protein has significant enzymatic
activity [16], or if it perhaps has evolved a regulatory function
dependent on the binding of PRPP similar to other members of
this gene family [23,24]. In addition, while PRTFDC1 has been




Figure 4. PRTFDC1 protein expression in the transgenic mice.
Western blots of 7 week old male whole brain protein extracts from
Hprt
2/0/Tg, Tg, and wild-type mice from transgenic line 9 were probed
with an antibody to PRTFDC1, which has a molecular weight of
25.7 kDa (top panel). Note the PRTFDC1 antibody cross-reacts with
HPRT (molecular weight=24.6 kDa) and that the two proteins are 68%
identical and 83% similar. A b-actin antibody was used as a loading
control (bottom panel). The positions of the molecular weight (kDa)
markers are indicated on the left and the proteins are labeled on the
right. Also note the band between 37 and 50 kDa in the top panel is
leftover signal from probing with the b-actin antibody, and no
additional band consistent with HPRT or PRTFDC1 dimers or tetramers
were visible on this blot.
doi:10.1371/journal.pone.0022381.g004
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PRTFDC1 could therefore provide a key piece of knowledge as to
how humans and mice differ in their direct or indirect regulatory
interactions with purine metabolites and enzymes, and ultimately
could lead to a better understanding and treatment of LND.
Supporting Information
Materials and Methods S1 Genotyping methods and the
protocol for confirming expression of the transgene
transcript.
(DOCX)
Figure S1 The genomic location of human BAC clone
RP11-129O7. The position of human BAC clone RP11-129O7 is
shown with respect to its position on chromosome 10 (hg18) and
PRTFDC1. The positions of PCR primers used in the identification
of the transgenic founders and genotyping and transgenic mice are
also shown.
(EPS)
Figure S2 The human PRTFDC1 gene is expressed in the
transgenic mice. RT-PCR using species and gene-specific
primers verified that the human PRTFDC1 gene was expressed in
the four lines of transgenic mice. An example of the RT-PCR
results for Tg(RP11-129O7)13 and Tg(RP11-129O7)36 p28 whole
brain cDNAs is shown (see Materials and Methods S1 for
methodological details). The left gel image is of the RT-PCR
product for human PRTFDC1 (200 bp) and the right gel image is a
control showing the RT-PCR product for endogenous mouse
Hprt1 (202 bp). Note that PRTFDC1 expression was also detected
in Tg(RP11-129O7)9 (see Fig. S6) and Tg(RP11-129O7)14.
(EPS)
Figure S3 Neither deficiency of HPRT nor the presence
of the PRTFDC1 transgene affect locomotor behavior.
Mice were placed in locomotor-monitoring chambers and
ambulations were recorded for 2 (a) or 24 (b) hours. Shown are
mean 6 SEM ambulations (consecutive beam breaks).
(TIF)
Figure S4 Dopamine levels in the nucleus accumbens
and olfactory bulbs. DA levels were measured in males (n=7–
14) from each genotype in the nucleus accumbens (a) and the
olfactory bulbs (b). * P,0.05 comparing Hprt
2/0 males (with or
without the transgene) with wild-type and Tg mice. No significant
differences between genotypes were seen in the olfactory bulbs.
(TIF)
Figure S5 Transcript profiles of HPRT1 and PRTFDC1
in human tissue. Relative transcript abundance of HPRT1
(black) and PRTFDC1 (white) per 1,000,000 ACTB molecules.
Total human RNA (Clontech and US Biologics) was used to
generate cDNA (in duplicate) using Superscript II Reverse
Transcriptase (Invitrogen) according to manufacture’s recommen-
dations. Quantitative RT-PCR reactions (n=4 replicates per
cDNA template) were performed using PlatinumH SYBRH Green
qPCR SuperMix-UDG (Invitrogen) and Roche LightCycler V3
using commercially available primers for human PRTFDC1 and
HPRT1 (SuperArray Bioscience Corp.).
(EPS)
Figure S6 Transcript profiles of PRTFDC1 in wild-type
and Hprt-deficient backgrounds. Relative transcript abun-
dance of PRTFDC1 in wild-type (black) and Hprt
2/0 (white)
backgrounds per 1,000,000 Actb molecules. No significant
differences in the abundance of PRTFDC1 were observed between
genotypes or transgenic lines 9 and 13. Tissues were dissected from
neonate (p0), juvenile (p28) and adult (7 week-old) males. Total
RNA was isolated and used as a template to generate cDNA using
commercially available primers for human PRTFDC1, and mouse-
specific primers Actb (SuperArray Bioscience Corp.).
(EPS)
Video S1 Nail-biting-like behavior in the Hprt
2/0/Tg
mice. The Hprt
2/0/Tg exhibit distinct amphetamine-induced
stereotypy that is reminiscent of nail-biting. The mice are in an
unusual hunched posture and display head-bobbing behavior
while simultaneously bringing their forepaws to their mouths and
moving their mouths in a chewing or biting manner.
(AVI)
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